Bright Minds Biosciences Inc.

NASDAQ:DRUG

Biotechnology

Healthcare
$20.76 +1.04%

+$0.62 today

Market cap
$204.78M
Beta
-0.11
P/E (TTM)
-29.8
EPS (TTM)
-$2.87
52W Low $23.18High $123.75

Volume 0.14M

Average 0.27M

DRUG Debt Repayment

Cash used to repay borrowings during the period.

Bright Minds Biosciences Inc.NASDAQ: DRUG

Debt Repayment · Q2 FY2026 · quarter ended Mar 2026

Debt repayment turns positive

Q2 FY2026 debt repayment was CA$0, compared with -CA$24.63K a year earlier. Trailing-twelve-month debt repayment was -CA$77.76K. Over 3 fiscal years it compounded at +140.9% a year.

Context

  • Debt repayment grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of -CA$19.44K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0+100.0% QoQ
Last fiscal yearSep 2025
-CA$100.15K+11.6% YoY
LTMMar 2026
-CA$77.76K-17.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+11.6%——
3-year CAGR+140.9%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

CAD · from the cash flow

Latest · FY2025
(100.15K) CAD
Year-over-year change
-11.6%

Debt Repayment vs competitors

How DRUG compares with its peers on the latest reported figures

No competitor Debt Repayment figures are available to compare.

Cash Flow Statement

CAD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Depreciation & Amortization06.04K72.45K73.36K76.87K
Deferred Income Tax00000
Stock-Based Compensation880.62K875.06K1.15M839.77K3.18M
Change in Working Capital306.08K724.13K(941.72K)39.81K554.99K
Accounts Receivables(110.15K)(45.63K)118.8K(13.24K)(362.85K)
Inventory00000
Accounts Payables00000
Other Working Capital416.23K769.77K(1.06M)53.06K917.84K
Other Non-Cash Items144.76K(227.4K)65.1K(1.18K)(276.84K)
Operating Cash Flow(7.32M)(13.59M)(7.02M)(1.85M)(8.69M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment0(7.16K)(86.11K)(89.73K)(100.15K)
Common Stock Issued27.74M4.03M1.22M900.3K86.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.69M)1.17M1.06M0(360.14K)
Financing Cash Flow26.06M5.2M2.19M810.57K85.57M
Effect of Forex Changes223.79K258.82K(45.35K)11.72K312.63K
Net Change in Cash18.96M(8.13M)(4.88M)(1.03M)77.19M
Free Cash Flow(7.32M)(13.59M)(7.02M)(1.85M)(8.69M)

Bright Minds Biosciences Inc.

NASDAQ:DRUG

Intrinsic Alpha fair value

Locked

Current Price

$20.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.